미국의 의약품 아이솔레이터 시장 : 시장 규모, 점유율, 동향 분석(유형별, 제품별), 부문별 예측(2025-2030년)

U.S. Pharmaceutical Isolators Market Growth & Trends:

The U.S. pharmaceutical isolators market size is expected to reach USD 222.6 million by 2030, registering a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rapid growth of the pharmaceutical industry in the U.S. and advancements in technologies used in the industry are anticipated to have a positive impact on market growth.

The growth of the industry in the U.S. is primarily driven by continuous progress in the field of medicines and bioscience. The rising demand for aseptically processed parenteral medicines, along with increased investments in the industry, is anticipated to drive the market in the U.S.

Pharmaceutical isolators are seeing fast-paced technological advancements in aseptic processing in terms of incorporation of robotics and automation solutions and industry 4.0. By integrating robotics within gloveless pharmaceutical isolators, the risk of microbe contamination, as well as particle contamination caused by human intervention is reduced.

The industry is moving toward energy efficiency and sustainability. Pharmaceutical isolators offer higher energy efficiency as compared to the Restricted Access Barrier System (RABS). Energy saving in pharmaceutical isolators can be up to 65% as compared to 30% offered by RABS which is likely to positively improve their demand.

U.S. Pharmaceutical Isolators Market Report Highlights:

• The closed isolators segment is expected to witness a CAGR of 5.7% from 2025 to 2030 owing to the ability to operate without personnel access to the critical zone, making them suitable for application in the preparation of toxic materials
• The positive pressure segment accounted for 54.6% of the overall revenue share in 2024, owing to its demand in sterile processes when the process is of particular significance and keeping any contaminants out of the isolator is a priority
• Companies are collaborating with educational institutions along with their in-house R&D facilities for developing processes and technologies that offer a sustainable advantage in the future
• In February 2021, Comecer S.p.A partnered with Illuminate Manufacturing Intelligence, to integrate Illuminate, a pharmaceutical production solution based on industry 4.0, to get real-time updates of their manufacturing equipment

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources & Third-Party Perspectives
  • 1.3.4. Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Data Visualization
• 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

• 2.1. Market Insights
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. U.S. Pharmaceutical Isolators Market Variables, Trends & Scope

• 3.1. U.S. Pharmaceutical Isolators Market Outlook
• 3.2. Industry Value Chain Analysis
• 3.3. Application Overview
• 3.4. Average Price Trend Analysis
• 3.5. Supply-Demand Gap Analysis, 2024
• 3.6. Regulatory Framework
  • 3.6.1. Policies and Incentive Plans
  • 3.6.2. Standards and Compliances
  • 3.6.3. Regulatory Impact Analysis
• 3.7. Market Dynamics
  • 3.7.1. Market Driver Analysis
  • 3.7.2. Market Restraint Analysis
  • 3.7.3. Industry Challenges
• 3.8. Porter's Five Forces Analysis
  • 3.8.1. Supplier Power
  • 3.8.2. Buyer Power
  • 3.8.3. Substitution Threat
  • 3.8.4. Threat From New Entrant
  • 3.8.5. Competitive Rivalry
• 3.9. PESTEL Analysis
  • 3.9.1. Political Landscape
  • 3.9.2. Economic Landscape
  • 3.9.3. Social Landscape
  • 3.9.4. Technological Landscape
  • 3.9.5. Environmental Landscape
  • 3.9.6. Legal Landscape

Chapter 4. U.S. Pharmaceutical Isolators Market: Type Outlook Estimates & Forecasts

• 4.1. U.S. Pharmaceutical Isolators Market: Type Movement Analysis, 2024 & 2030
  • 4.1.1. Open Isolator
    • 4.1.1.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 4.1.2. Closed Isolator
    • 4.1.2.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Pharmaceutical Isolators Market: Product Outlook Estimates & Forecasts

• 5.1. U.S. Pharmaceutical Isolators Market: Product Movement Analysis, 2024 & 2030
  • 5.1.1. Positive Pressure
    • 5.1.1.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 5.1.2. Negative Pressure
    • 5.1.2.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Vendor Landscape
  • 6.2.1. Company Categorization
  • 6.2.2. List Of Key Distributors and Channel Partners
  • 6.2.3. List Of Potential Customers/End Users
• 6.3. Competitive Dynamics
  • 6.3.1. Competitive Benchmarking
  • 6.3.2. Strategy Mapping
  • 6.3.3. Heat Map Analysis
• 6.4. Company Profiles/Listing
  • 6.4.1. COMECER S.p.A.
    • 6.4.1.1. Participant's Overview
    • 6.4.1.2. Financial Performance
    • 6.4.1.3. Product Benchmarking
    • 6.4.1.4. Strategic Initiatives
  • 6.4.2. LAF Technologies
    • 6.4.2.1. Participant's Overview
    • 6.4.2.2. Financial Performance
    • 6.4.2.3. Product Benchmarking
    • 6.4.2.4. Strategic Initiatives
  • 6.4.3. Iso Tech Design
    • 6.4.3.1. Participant's Overview
    • 6.4.3.2. Financial Performance
    • 6.4.3.3. Product Benchmarking
    • 6.4.3.4. Strategic Initiatives
  • 6.4.4. Nuaire
    • 6.4.4.1. Participant's Overview
    • 6.4.4.2. Financial Performance
    • 6.4.4.3. Product Benchmarking
    • 6.4.4.4. Strategic Initiatives
  • 6.4.5. Getinge AB
    • 6.4.5.1. Participant's Overview
    • 6.4.5.2. Financial Performance
    • 6.4.5.3. Product Benchmarking
    • 6.4.5.4. Strategic Initiatives
  • 6.4.6. SKAN AG
    • 6.4.6.1. Participant's Overview
    • 6.4.6.2. Financial Performance
    • 6.4.6.3. Product Benchmarking
    • 6.4.6.4. Strategic Initiatives
  • 6.4.7. M. BRAUN INERTGAS-SYSTEME GMBH
    • 6.4.7.1. Participant's Overview
    • 6.4.7.2. Financial Performance
    • 6.4.7.3. Product Benchmarking
    • 6.4.7.4. Strategic Initiatives
  • 6.4.8. I.M.A. SpA
    • 6.4.8.1. Participant's Overview
    • 6.4.8.2. Financial Performance
    • 6.4.8.3. Product Benchmarking
    • 6.4.8.4. Strategic Initiatives
  • 6.4.9. AZBIL TELSTAR, S.L.U.
    • 6.4.9.1. Participant's Overview
    • 6.4.9.2. Financial Performance
    • 6.4.9.3. Product Benchmarking
    • 6.4.9.4. Strategic Initiatives
  • 6.4.10. Syntegon Technologies GmbH
    • 6.4.10.1. Participant's Overview
    • 6.4.10.2. Financial Performance
    • 6.4.10.3. Product Benchmarking
    • 6.4.10.4. Strategic Initiatives